IP Library Granted Patent US 11,021,458
Granted Patent B2
US 11,021,458 · App. 16/511,642 · Granted Jun 1, 2021

Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors

Inventors: Pravin L. Kotian (Hoover, AL); Yarlagadda S. Babu (Birmingham, AL); Weihe Zhang (Vestavia, AL); Peng-Cheng Lu (Hoover, AL); Minwan Wu (Vestavia Hills, AL); Wei Lv (Hoover, AL); Trung Xuan Nguyen (Hoover, AL); Zhao Dang (Vestavia Hills, AL); Venkat R. Chintareddy (Vestavia Hills, AL); V. Satish Kumar (Birmingham, AL); Krishnan Raman (Birmingham, AL)
Assignee: BioCryst Pharmaceuticals, Inc.
C07D401/10C07D209/12C07D261/20C07D307/80C07D333/64C07D401/12C07D405/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,021,458
App. No.
16/511,642
Granted
Jun 1, 2021
Kind
B2
Abstract

Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

Claims (15)

1. A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

2. The compound of claim 1 , wherein the compound is in the form of a hydrochloride salt.

3. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 3 , wherein the compound is in the form of a hydrochloride salt.

5. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 5 , wherein the compound is in the form of a hydrochloride salt.

7. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 7 , wherein the compound is in the form of a hydrochloride salt.

9. A pharmaceutical composition, comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

10. A pharmaceutical composition, comprising the compound of claim 3 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

11. A pharmaceutical composition, comprising the compound of claim 5 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

12. A pharmaceutical composition, comprising the compound of claim 7 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Assignments (4)
SECURITY INTEREST Recorded Jan 23, 2026
From: BIOCRYST PHARMACEUTICALS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 074485/0651 →
RELEASE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Apr 18, 2023
From: ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP
To: BIOCRYST PHARMACEUTICALS, INC.
Reel/Frame 063362/0550 →
SECURITY INTEREST Recorded Apr 10, 2023
From: BIOCRYST PHARMACEUTICALS, INC.
To: ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP
Reel/Frame 063284/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2019
From: KOTIAN, PRAVIN L.; BABU, YARLAGADDA S.; ZHANG, WEIHE; LU, PENG-CHENG; WU, MINWAN; LV, WEI; NGUYEN, TRUNG XUAN; DANG, ZHAO; CHINTAREDDY, VENKAT R.; KUMAR, V. SATISH; RAMAN, KRISHNAN
To: BIOCRYST PHARMACEUTICALS, INC.
Reel/Frame 049804/0154 →